aTyr Pharma (NSDQ:LIFE) said today that its candidate Resolaris was granted fast track designation by the FDA for the treatment of facioscapulohumeral muscular dystrophy, making it the 1st therapeutic candidate to receive the designation for the rare form of muscular dystrophy.
Resolaris is derived from a naturally occurring protein released by human skeletal muscle cells. aTyr is exploring the use of Resolaris as a therapy for patients with rare myopathies with an immune component characterized by excessive immune cell involvement.
Get the full story at our sister site, Drug Delivery Business News.
The post aTyr Pharma wins FDA Fast Track Designation for muscular dystrophy therapy appeared first on MassDevice.
from MassDevice http://ift.tt/2ehtK9l
Cap comentari:
Publica un comentari a l'entrada